血友病市场规模、份额和成长分析（按类型、产品、疗法、治疗和地区）- 产业预测（2025-2032 年）

2023 年血友病市场规模价值 135 亿美元，预计将从 2024 年的 143.9 亿美元成长到 2032 年的 240 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.6%。

受近期基因疗法核准及一群前景看好的候选药物的推动，血友病治疗市场预计将出现强劲成长。人们对血友病的认识不断提高，加上政府对新生儿早期检测的倡议，进一步促进了市场的扩张。根据世界血友病联盟统计，截至2021年10月，血友病主要影响男性，全球通报盛行率为209,614例，其中A型165,379例，B型33,076例，未知类型11,159例。高发病率刺激了可用治疗方法的激增，并凸显了该领域对有效治疗方法和创新的迫切需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场进行机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

血友病市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• A型血友病A
• B型血友病
• 血友病C
• 其他的

血友病市场规模（依产品和复合年增长率） (2025-2032)

• 市场概况
• 血浆来源的凝血因子浓缩物
• 重组凝血因子浓缩物
• 去氨加压素和抗纤溶药物

血友病市场规模（依疗法和复合年增长率） (2025-2032)

• 市场概况
• 一经请求
• 预防

血友病市场规模（依治疗方式及复合年增长率） (2025-2032)

• 市场概况
• 替代疗法
• ITI 治疗
• 基因治疗

血友病市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• 拜耳公司（德国）
• BioMarin製药公司（美国）
• CSL Behring（澳洲）
• Kedrion（Italy）
• 诺和诺德（丹麦）
• 辉瑞公司（美国）
• 罗氏（中外製药株式会社）（瑞士/日本）
• 赛诺菲（健赞公司）（法国／美国）
• 武田製药（Shire Plc.）（日本/爱尔兰）
• Grifols（西班牙）
• Octapharma（瑞士）
• F. Hoffmann-La Roche Ltd（瑞士）
• Biogen（美国）
• Baxalta（美国）
• LFB集团（法国）
• Bioverativ Inc.（美国）
• 生物产品实验室有限公司（英国）
• Kogenate（德国）
• Sangamo Therapeutics, Inc.（美国）

结论和建议

Hemophilia Market size was valued at USD 13.5 billion in 2023 and is poised to grow from USD 14.39 billion in 2024 to USD 24.0 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The hemophilia treatment market is poised for robust growth, spurred by recent gene therapy approvals and a pipeline of promising developmental candidates. Heightened awareness of hemophilia, alongside government initiatives for early neonatal detection, is further catalyzing market expansion. According to the World Federation of Hemophilia, as of October 2021, hemophilia predominantly affects males, with a reported global prevalence of 209,614 cases-165,379 of which are type A, 33,076 type B, and 11,159 of unknown type. The substantial prevalence rates are fueling increased adoption of available therapies, underscoring the urgent need for effective treatments and innovation within the sector, thereby positioning hemophilia management as a critical area of focus for healthcare providers and pharmaceutical companies alike.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and Region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is being driven by significant advancements in medical technology, particularly in gene therapy, recombinant factor concentrates, and personalized medicine. These innovations have revolutionized treatment strategies, offering patients improved therapeutic options that lead to better health outcomes and enhanced quality of life. As these cutting-edge therapies continue to evolve, they are not only transforming the management of hemophilia but also fostering a more tailored approach to treatment that resonates with individual patient needs. Consequently, the growing adoption of these advanced therapies is a key factor propelling the hemophilia market forward.

Restraints in the Hemophilia Market

The hemophilia market faces significant restraints primarily due to the high costs associated with treatment options, especially with the advent of novel therapies like gene therapy. These advancements, while promising, often come with hefty price tags that can create financial burdens for patients and healthcare systems alike. This economic barrier restricts access to cutting-edge treatments, which may hinder patient outcomes and overall disease management. Consequently, the financial implications of these innovative therapies remain a critical challenge within the hemophilia market, impacting the availability and accessibility of essential care for those affected by this bleeding disorder.

Market Trends of the Hemophilia Market

The hemophilia market is experiencing a significant shift towards gene therapy as a transformative treatment modality. This trend is driven by the increasing recognition of gene therapy's potential to address the root genetic causes of hemophilia, offering patients durable solutions that could replace the need for traditional factor replacement therapies. Advances in viral vector technologies and a deeper understanding of genetic engineering have catalyzed this shift, leading to numerous successful clinical trials that validate the efficacy and safety of gene therapies. As these innovations continue to unfold, they promise to enhance patient quality of life, reduce treatment frequency, and reshape the overall landscape of hemophilia care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Global Hemophilia Market Size by Product & CAGR (2025-2032)

• Market Overview
• Plasma derived coagulation factor concentrates
• Recombinant coagulation factor concentrates
• Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• On-demand
• Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Replacement therapy
• ITI therapy
• Gene Therapy

Global Hemophilia Market Size & CAGR (2025-2032)

• North America (Type, Product, Therapy, Treatment)
  • US
  • Canada
• Europe (Type, Product, Therapy, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Therapy, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Therapy, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Therapy, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Genzyme Corporation) (France/United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxalta (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kogenate (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations